Vertex's cystic fibrosis drug shows promise in Phase II trial

04/19/2013 | Reuters

Cystic fibrosis patients who took Vertex Pharmaceuticals' experimental drug VX-661, in combination with Kalydeco, or ivacaftor, experienced improvement in lung function compared with those who received a placebo, a midstage trial found. The drug, alone or in combination with Kalydeco, was also well-tolerated by patients.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC